This competitive renewal application for a Specialized Program of Research Excellence (SPORE) in Cervical Cancer at Johns Hopkins University School of Medicine, University of Alabama at Birmingham, University of Colorado and our new collaborator Mount Sinai Icahn School of Medicine brings together a highly interactive, multidisciplinary, and inter-institutional program of translational research in cervical cancer. Th SPORE includes five integrated projects spanning the fields of prevention and treatment cervical cancer and its precursor lesions. Project 1: L1 capsomeres as a next generation preventive HPV vaccine, led by Robert Garcea, M.D. and Warner Huh, M.D. Project 2: Local vaccination and imiquimod for persistent HPV16+ patients with normal cytology, led by Richard Roden, Ph.D., Warner Huh, M.D. and T.-C. Wu, M.D., Ph.D. Project 3: Treatment of HIV- and HIV+ patients with CIN2/3 using an HPV DNA vaccine administered intramuscularly via electroporation, led by Ronald Alvarez, M.D., Chien-Fu Hung, Ph.D. and Richard Roden, Ph.D. Project 4: Molecular attributes of tissue immune response in HPV disease, led by Cornelia Trimble, M.D. and Michael Donovan, M.D., Ph.D. Project 5: Safety and immunogenicity study of a HPV16-specific therapeutic protein administered intratumorally during chemoradiation, led by Ronald Alvarez, M.D., Richard Roden, Ph.D. and T.-C. Wu, M.D., Ph.D. The five integrated projects are supported by three cores that provide critical supportive infrastructure essential to efficient and effective translational research: the Administrative/Communication Core (Core A), led by T.-C. Wu, M.D., Ph.D. and Edward Partridge, M.D., the Biostatistics/Data Management Core (Core B), led by Sejong Bae Ph.D., Karan Singh, Ph.D., and Chenguang Wang, Ph.D. and the Tissue/Pathology and Immunology Core (Core C), led by Cornelia Trimble, M.D. and Lawrence Lamb, Ph.D. The SPORE also includes a Developmental Research Program (led by T.- C. Wu, M.D., Ph.D. and Drew Pardoll M.D., Ph.D.) to nurture novel research ideas and technologies and a Career Development Program (led by T.-C. Wu, M.D., Ph.D. and Edward Partridge, M.D.) to recruit and facilitate career development of individuals with interest in translational cervical cancer research.

Public Health Relevance

This research program provides a spectrum of capabilities, driving innovative translational research for improved prevention and treatment of cervical cancer to better patient outcomes and our understanding of cancer biology and immunology

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (M1))
Program Officer
Kuzmin, Igor A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Sinno, A K; Li, X; Thompson, R E et al. (2017) Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care. Gynecol Oncol 145:493-499
Stewart, Katherine Ikard; Fader, Amanda N (2017) New Developments in Minimally Invasive Gynecologic Oncology Surgery. Clin Obstet Gynecol 60:330-348
Jiang, Rosie T; Wang, Joshua W; Peng, Shiwen et al. (2017) Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection. J Virol 91:
Yoo, Wonsuk; Kim, Sangmi; Huh, Warner K et al. (2017) Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States. PLoS One 12:e0172548
Moukarzel, Lea A; Angarita, Ana M; VandenBussche, Christopher et al. (2017) Preinvasive and Invasive Cervical Adenocarcinoma: Preceding Low-Risk or Negative Pap Result Increases Time to Diagnosis. J Low Genit Tract Dis 21:91-96
Huh, Warner K; Guido, Richard (2017) Transitioning from HPV 101 to HPV 202. Am J Obstet Gynecol 216:206-207
Yang, Pei-Ming; Chou, Chia-Jung; Tseng, Ssu-Hsueh et al. (2017) Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma. Oncotarget 8:46145-46162
Fader, Amanda N (2017) Minimally Invasive Techniques for Treating Gynecologic Malignancies. J Natl Compr Canc Netw 15:730-732
Mehta, Ambar; Xu, Tim; Hutfless, Susan et al. (2017) Patient, surgeon, and hospital disparities associated with benign hysterectomy approach and perioperative complications. Am J Obstet Gynecol 216:497.e1-497.e10
Yang, Andrew; Farmer, Emily; Lin, John et al. (2017) The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res 231:148-165

Showing the most recent 10 out of 273 publications